SCHEMBL4334926

SCHEMBL4334926

Cc1cccc(-c2noc(N)c2-c2ccncc2)c1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.52
MLYCD O95822 2/20 0.45
BRD4 O60885 1/20 0.42
TDO2 P48775 1/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
NUDT1 P36639 1/20 0.39
PTGS1 P23219 2/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP17A1 P05093 2/20 0.37
CYP1A2 P05177 1/20 0.37
PTGS2 P35354 1/20 0.37
ACE2 Q9BYF1 1/20 0.37
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
MAPK11 Q15759 1/20 0.36
LRRK2 Q5S007 1/20 0.36
TGFBR1 P36897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4332040 0.89 MAPK14 (0.55) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL4334913 0.87 MAPK14 (0.59) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL1879545 0.83 MAPK14 (0.54) MAPK14BRD4TDO2LMNANUDT1
SCHEMBL4334747 0.78 MAPK14 (0.59) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL4336223 0.78 ALDH1A1 (0.55) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL4336987 0.78 MAPK14 (0.52) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL4480878 0.77 MAPK14 (0.55) MAPK14MLYCDBRD4TDO2LMNA
SCHEMBL4341555 0.76 MAPK14 (0.51) MAPK14MLYCDALDH1A1MAPTHSP90AA1
SCHEMBL4338473 0.76 MAPK14 (0.57) MAPK14MLYCDBRD4TDO2PTGS1
SCHEMBL4334611 0.76 MAPK14 (0.57) MAPK14MLYCDLMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036905-B1 PYRIDYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2012-12-12 EP disclosed
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885MLYCD 4475/4885BRD4 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.